Tech's hottest IPOs of the year, including Beyond Meat and Zoom, dropped on Monday, falling more than the broader market.Technologyread more
"We do not seek conflict with Iran or any other country," Trump tells reporters in the Oval Office.Politicsread more
Stocks in Asia were tepid in Tuesday morning trade, while investors looked toward to a meeting between U.S. President Donald Trump and Chinese President Xi Jinping set to...Asia Marketsread more
Chinese Vice Premier Liu He held a phone conversation with U.S. Trade Representative Robert Lighthizer and U.S. Treasury Secretary Steven Mnuchin, China's Ministry of Commerce...World Economyread more
Sen. Bernie Sanders announced a plan Monday to forgive the country's $1.6 trillion outstanding student loan tab, intensifying the higher education policy debate in the 2020...Personal Financeread more
While earnings usually come in substantially ahead of expectations — as much as 4 or 5 percentage points is not unusual — the downward direction in the outlook doesn't speak...Earningsread more
U.S. President Donald Trump's senior adviser Kellyanne Conway will not testify before the House of Representatives Oversight Committee this week on her alleged violations of...Politicsread more
"We missed being the dominant mobile operating system by a very tiny amount. We were distracted during our antitrust trial. We didn't assign the best people to do the work,"...Technologyread more
PatientsLikeMe was bought by UnitedHealth following a review by Trump's Treasury Department, which scrutinized the start-up because it's backed by Chinese cash.Technologyread more
Some traders think the energy rally is about to wane, despite the sector being one of June's big winners.ETF Edgeread more
Stocks with this one feature are poised to crush the market after a rate cut, according to Goldman Sachs.Marketsread more
For critically ill diabetes patients, making sure their blood sugar levels are correct is crucial. If they drop then glucose needs to be administered, but if they rise too high then insulin is required.
Currently, this is done by nurses in hospitals, but one start-up has created an "artificial pancreas" that can automate the process, and it's a chip that's smaller than a thumbnail.
Boston, MA.-based Admetsys has created a solution that can constantly monitor blood sugar levels in real time. It's artificial intelligence (AI) algorithm then triggers its software to either administer glucose or insulin via the drip that a patient is connected to.
The drip is connected to a screen. The screen shows the metrics for the patient.
"It is a laboratory on a chip. This is what will be able to replace what is in the laboratory," Timothy Valk, co-founder of Admetsys, told CNBC in an interview that aired Friday.
The company's solution doesn't require human intervention. Valk said rather than lead to job losses in hospitals, it would help medical professionals focus on harder tasks.
"This device was suggested … by nurses. The nurses' workload is astronomical. They need to be doing other things that are more appropriate for them, than running in and manually doing a glucose or drawing blood … their time is costly," Valk said.
"We need to have automation work to improve the capacity for nurses and doctors to do the more appropriate, high risk needed jobs, and less of the manual techniques."
Admetsys is part of the Dubai Future Accelerators program where start-ups work with various government agencies to come up with technology solutions.
Valk, who spoke with CNBC in Dubai, estimates that the technology can save a hospital around $8,000 per patient and reduce the amount of time that they would stay in intensive care.
Admetsys has currently done three successful clinical trials for the U.S. Food and Drug Administration which regulates medical technologies. It was required to keep blood sugar levels within a defined range for a period of time. Admetsys said that it is also going to carry out a clinical trial soon in Denmark which will help it be regulated in Europe. And it hopes that the FDA will give it approval within the year.
Valk said that regulators were becoming more open to new medical technologies.
"There is no doubt that as technology has advanced that they have become much more open," he told CNBC.